“Limb Girdle Muscular Dystrophy Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Limb Girdle Muscular Dystrophy Market.

The Limb Girdle Muscular Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Limb Girdle Muscular Dystrophy Pipeline Report:

• Companies across the globe are diligently working toward developing novel Limb Girdle Muscular Dystrophy treatment therapies with a considerable amount of success over the years. Limb Girdle Muscular Dystrophy Key players such as – Catabasis Pharmaceuticals, Sarepta Therapeutics, Strykagen, Sarepta Therapeutics, aTyr Pharma, ML Bio Solutions, and others, are developing therapies for the Limb Girdle Muscular Dystrophy treatment

• Limb Girdle Muscular Dystrophy Emerging therapies such as – CAT-1004, SRP-9005, Stryka 516s, MYO 102, SRP-9003, ATYR1940, BBP-418, and others are expected to have a significant impact on the Limb Girdle Muscular Dystrophy market in the coming years.

• In June 2025, Sarepta Therapeutics has been granted platform technology designation by the FDA for the rAAVrh74 viral vector used in bidridistrogene xeboparvovec (SRP-9003). This investigational gene therapy, which utilizes an adeno-associated virus (AAV) vector, is being developed for the treatment of limb-girdle muscular dystrophy Type 2E (LGMD2E/R4), also known as beta sarcoglycanopathy.

• In March 2025, AskBio Inc., a gene therapy company fully owned and independently operated by Bayer AG, has announced the progression of its Phase 1/2 LION-CS101 clinical trial evaluating the investigational gene therapy AB-1003 for patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The trial has moved forward with the dosing of the first participant in the second cohort. This advancement follows a safety review by an independent Data Safety Monitoring Board (DSMB), which reviewed recruitment and safety data from the first cohort and concluded it was safe to proceed. DSMBs are expert panels that assess clinical trial data to evaluate safety, risk-benefit profiles, and any unexpected adverse effects.

Limb Girdle Muscular Dystrophy Overview

Limb-girdle muscular dystrophy (LGMD) refers to a group of inherited muscle disorders characterized by progressive weakness and wasting of the muscles around the hips and shoulders, known as the limb-girdle muscles. There are several subtypes of LGMD, each caused by mutations in different genes that play a role in muscle structure and function.

Get a Free Sample PDF Report to know more about Limb Girdle Muscular Dystrophy Pipeline Assessment- https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight

Emerging Limb Girdle Muscular Dystrophy Drugs Under Different Phases of Clinical Development Include:

• CAT-1004: Catabasis Pharmaceuticals

• SRP-9005: Sarepta Therapeutics

• Stryka 516s: Strykagen

• MYO 102: Sarepta Therapeutics

• SRP-9003: Sarepta Therapeutics

• ATYR1940: aTyr Pharma

• BBP-418: ML Bio Solutions

Limb Girdle Muscular Dystrophy Pipeline Therapeutics Assessment

• Limb Girdle Muscular Dystrophy Assessment by Product Type

• Limb Girdle Muscular Dystrophy By Stage and Product Type

• Limb Girdle Muscular Dystrophy Assessment by Route of Administration

• Limb Girdle Muscular Dystrophy By Stage and Route of Administration

• Limb Girdle Muscular Dystrophy Assessment by Molecule Type

• Limb Girdle Muscular Dystrophy by Stage and Molecule Type

DelveInsight’s Limb Girdle Muscular Dystrophy Report covers around 25+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Download Sample PDF Report to know more about Limb Girdle Muscular Dystrophy drugs and therapies

Limb Girdle Muscular Dystrophy Pipeline Analysis:

The Limb Girdle Muscular Dystrophy pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the Limb Girdle Muscular Dystrophy treatment with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Limb Girdle Muscular Dystrophy Treatment.

• Limb Girdle Muscular Dystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Limb Girdle Muscular Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Limb Girdle Muscular Dystrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Limb Girdle Muscular Dystrophy product details are provided in the report. Download the Limb Girdle Muscular Dystrophy pipeline report to learn more about the emerging Limb Girdle Muscular Dystrophy therapies

Limb Girdle Muscular Dystrophy Pipeline Market Drivers

• Increasing awareness about available treatment options

• A better understanding of disease pathogenesis

Limb Girdle Muscular Dystrophy Pipeline Market Barriers

• No cure exists for any form of Limb Girdle Muscular Dystrophy

• Lack of proper Genetic Counselling, which is to be given to individuals and their families.

Scope of Limb Girdle Muscular Dystrophy Pipeline Drug Insight

• Coverage: Global

• Key Limb Girdle Muscular Dystrophy Companies: Catabasis Pharmaceuticals, Sarepta Therapeutics, Strykagen, Sarepta Therapeutics, aTyr Pharma, ML Bio Solutions, and others

• Key Limb Girdle Muscular Dystrophy Therapies: CAT-1004, SRP-9005, Stryka 516s, MYO 102, SRP-9003, ATYR1940, BBP-418, and others

• Limb Girdle Muscular Dystrophy Therapeutic Assessment: Limb Girdle Muscular Dystrophy current marketed and Limb Girdle Muscular Dystrophy emerging therapies

• Limb Girdle Muscular Dystrophy Market Dynamics: Limb Girdle Muscular Dystrophy market drivers and Limb Girdle Muscular Dystrophy market barriers

Request for Sample PDF Report for Limb Girdle Muscular Dystrophy Pipeline Assessment and clinical trials

Table of Contents

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/